|
TR200001942T2
(tr)
|
1997-12-22 |
2000-11-21 |
Euro-Celtique, S.A. |
Opioid agonist/antagonist kombinasyonlar
|
|
CN1204890C
(zh)
*
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
|
US6375957B1
(en)
*
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
EP2295043A1
(en)
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
|
SI2283842T1
(sl)
*
|
2000-02-08 |
2015-07-31 |
Euro-Celtique S.A. |
Oralne formulacije opioidnih agonistov, varne pred zlorabo
|
|
AU2002227383B2
(en)
|
2000-10-30 |
2004-07-08 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
US7858118B2
(en)
*
|
2001-04-11 |
2010-12-28 |
Galephar Pharmaceutical Research, Inc. |
Extended release composition containing Tramadol
|
|
ATE345112T1
(de)
*
|
2001-05-11 |
2006-12-15 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
|
EP1387673B1
(en)
*
|
2001-05-11 |
2010-12-29 |
Endo Pharmaceuticals Inc. |
Abuse-resistant controlled-release opioid dosage form
|
|
US7968119B2
(en)
*
|
2001-06-26 |
2011-06-28 |
Farrell John J |
Tamper-proof narcotic delivery system
|
|
DK1404331T3
(da)
*
|
2001-07-06 |
2008-01-28 |
Penwest Pharmaceuticals Co |
Sustained release-formuleringer af oxymorphon
|
|
KR20030034171A
(ko)
|
2001-07-06 |
2003-05-01 |
엔도 파마슈티걸즈, 인크. |
옥시모르폰 제어 방출 제형
|
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
|
DK1416842T3
(da)
*
|
2001-07-18 |
2009-03-16 |
Euro Celtique Sa |
Farmaceutiske kombinationer af oxycodon og naloxon
|
|
US7144587B2
(en)
*
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
|
US7141250B2
(en)
*
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
|
ES2326794T3
(es)
|
2001-08-06 |
2009-10-20 |
Euro-Celtique S.A. |
Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
|
|
US20030157168A1
(en)
*
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
|
US7332182B2
(en)
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
|
US7842307B2
(en)
*
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
US20030049317A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Lindsay David R. |
Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
|
|
WO2003026743A2
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
|
US7056500B2
(en)
|
2001-10-18 |
2006-06-06 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of opioid antagonists
|
|
WO2003039561A1
(en)
*
|
2001-11-02 |
2003-05-15 |
Elan Corporation, Plc |
Pharmaceutical composition
|
|
US20060177381A1
(en)
*
|
2002-02-15 |
2006-08-10 |
Howard Brooks-Korn |
Opiopathies
|
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
|
AU2003219863C1
(en)
*
|
2002-02-22 |
2009-03-05 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
|
AU2003220290B2
(en)
*
|
2002-03-14 |
2007-06-14 |
Euro-Celtique S.A. |
Naltrexone hydrochloride compositions
|
|
GB0206505D0
(en)
*
|
2002-03-19 |
2002-05-01 |
Euro Celtique Sa |
Pharmaceutical combination
|
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
|
PT1578350E
(pt)
*
|
2002-03-26 |
2009-08-27 |
Euro Celtique Sa |
Composições revestidas com geles de libertação constante
|
|
LT2425821T
(lt)
|
2002-04-05 |
2017-07-25 |
Euro-Celtique S.A. |
Farmacinis preparatas, turintis oksikodono ir naloksono
|
|
JP4732696B2
(ja)
|
2002-04-09 |
2011-07-27 |
フラメル・テクノロジー |
活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
|
|
ES2314227T7
(es)
*
|
2002-04-09 |
2012-11-19 |
Flamel Technologies |
Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
|
|
CA2496454A1
(en)
|
2002-04-23 |
2003-11-06 |
Alza Corporation |
Transdermal analgesic systems with reduced abuse potential
|
|
US20040156844A1
(en)
*
|
2002-05-22 |
2004-08-12 |
Curtis Wright |
Tamper resistant oral dosage form
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
|
WO2004004693A1
(en)
|
2002-07-05 |
2004-01-15 |
Collgegium Pharmaceutical |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
|
US8840928B2
(en)
*
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
CN1674903A
(zh)
*
|
2002-07-11 |
2005-09-28 |
大鹏药品工业株式会社 |
经鼻吸收用组合物
|
|
MY142204A
(en)
|
2002-07-25 |
2010-10-29 |
Pharmacia Corp |
Pramipexole once-daily dosage form
|
|
DE10237056A1
(de)
*
|
2002-08-09 |
2004-03-04 |
Grünenthal GmbH |
Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin
|
|
CA2495564A1
(en)
*
|
2002-08-15 |
2005-01-27 |
Euro-Celtique S.A. |
Pharmaceutical compositions
|
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
|
SI1551372T1
(en)
|
2002-09-20 |
2018-08-31 |
Alpharma Pharmaceuticals Llc |
SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
|
|
JP5189242B2
(ja)
*
|
2002-09-23 |
2013-04-24 |
アルケルメス ファーマ アイルランド リミテッド |
乱用抵抗性の医薬組成物
|
|
DE10250084A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
AU2003287364A1
(en)
|
2002-10-31 |
2004-06-07 |
Euro-Celtique S.A. |
Pharmaceutical identification
|
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
|
US7524515B2
(en)
*
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
|
DE10305137A1
(de)
*
|
2003-02-07 |
2004-08-26 |
Novosis Ag |
Transdermale therapeutische Abgabesysteme mit einem Butenolid
|
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
|
JP5501553B2
(ja)
*
|
2003-04-21 |
2014-05-21 |
ユーロ−セルティーク エス．エイ． |
同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
|
|
KR101167579B1
(ko)
|
2003-04-29 |
2012-07-27 |
오렉시젠 세러퓨틱스 인크. |
체중감량용 조성물
|
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
|
BRPI0409945A
(pt)
*
|
2003-04-30 |
2006-04-25 |
Purdue Pharma Lp |
forma de dosagem resistente à alteração
|
|
WO2004112756A1
(en)
*
|
2003-06-26 |
2004-12-29 |
Isa Odidi |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
PT1842533E
(pt)
*
|
2003-08-06 |
2013-05-17 |
Gruenenthal Gmbh |
Forma de dosagem protegida contra abuso
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE10361596A1
(de)
*
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
MXPA06003392A
(es)
*
|
2003-09-25 |
2006-06-08 |
Euro Celtique Sa |
Combinacion farmaceutica de hidrocodona y naltrexona.
|
|
SI1663229T1
(sl)
*
|
2003-09-25 |
2010-08-31 |
Euro Celtique Sa |
Farmacevtske kombinacije hidrokodona in naltreksona
|
|
WO2005037318A2
(en)
*
|
2003-10-15 |
2005-04-28 |
Pain Therapeutics, Inc. |
Treatment of arthritic conditions, chronic inflammation or pain
|
|
US20050245557A1
(en)
*
|
2003-10-15 |
2005-11-03 |
Pain Therapeutics, Inc. |
Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
|
|
AU2004286852A1
(en)
|
2003-10-30 |
2005-05-19 |
Alza Corporation |
Transdermal analgesic systems having reduced abuse potential
|
|
EP1691892B1
(en)
*
|
2003-12-09 |
2007-02-28 |
Euro-Celtique S.A. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
|
US8883204B2
(en)
*
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
|
GB0501638D0
(en)
*
|
2005-01-28 |
2005-03-02 |
Euro Celtique Sa |
Particulates
|
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
|
EP1718258B1
(en)
*
|
2004-02-23 |
2009-03-25 |
Euro-Celtique S.A. |
Abuse resistance opioid transdermal delivery device
|
|
TWI365880B
(en)
*
|
2004-03-30 |
2012-06-11 |
Euro Celtique Sa |
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
|
|
DK1729730T3
(da)
*
|
2004-03-30 |
2009-03-23 |
Euro Celtique Sa |
Manipulationssikker doseringsform, der omfatter et adsorberende stof og et kontramiddel
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
|
UA88477C2
(ru)
|
2004-08-13 |
2009-10-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
|
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
|
US7226619B1
(en)
|
2004-09-07 |
2007-06-05 |
Pharmorx Inc. |
Material for controlling diversion of medications
|
|
US7827983B2
(en)
*
|
2004-12-20 |
2010-11-09 |
Hewlett-Packard Development Company, L.P. |
Method for making a pharmaceutically active ingredient abuse-prevention device
|
|
KR100905511B1
(ko)
*
|
2005-01-28 |
2009-07-01 |
유로-셀띠끄 소시에떼 아노님 |
알코올 저항성 제형
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
FR2881652B1
(fr)
*
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
|
FR2889810A1
(fr)
*
|
2005-05-24 |
2007-02-23 |
Flamel Technologies Sa |
Forme medicamenteuse orale, microparticulaire, anti-mesurage
|
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
DK1895994T3
(da)
|
2005-05-13 |
2010-12-20 |
Alza Corp |
Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
|
|
WO2006124890A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Alpharma, Inc. |
Morphine sulphate formulations
|
|
WO2006124898A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Alpharma, Inc. |
Morphine sulfate formulations
|
|
ES2277743B2
(es)
*
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
|
WO2006133733A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Flamel Technologies |
Oral dosage form comprising an antimisuse system
|
|
AU2006275476A1
(en)
*
|
2005-08-01 |
2007-02-08 |
Alpharma Inc. |
Alcohol resistant pharmaceutical formulations
|
|
BRPI0614143A2
(pt)
|
2005-08-02 |
2012-11-20 |
Sol Gel Technologies Ltd |
processo para revestir um material particulado insolével em Água, sàlido, com um àxido metÁlico, material particulado revestido, composiÇço, mÉtodo para o tratamento de uma condiÇço superficial em um induvÍduo, e, uso de material particulado revestido
|
|
US9125833B2
(en)
*
|
2005-11-02 |
2015-09-08 |
Relmada Therapeutics, Inc. |
Multimodal abuse resistant and extended release opioid formulations
|
|
US8329744B2
(en)
*
|
2005-11-02 |
2012-12-11 |
Relmada Therapeutics, Inc. |
Methods of preventing the serotonin syndrome and compositions for use thereof
|
|
US20090082466A1
(en)
*
|
2006-01-27 |
2009-03-26 |
Najib Babul |
Abuse Resistant and Extended Release Formulations and Method of Use Thereof
|
|
US8652529B2
(en)
*
|
2005-11-10 |
2014-02-18 |
Flamel Technologies |
Anti-misuse microparticulate oral pharmaceutical form
|
|
PT2135603E
(pt)
|
2005-11-22 |
2013-04-03 |
Orexigen Therapeutics Inc |
Composições e métodos para aumentar a sensibilidade à insulina
|
|
US9522188B2
(en)
|
2005-12-13 |
2016-12-20 |
Biodelivery Sciences International, Inc. |
Abuse resistant transmucosal drug delivery device
|
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
EP1810714A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
|
|
EP1810678A1
(de)
†
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
|
|
RU2433817C2
(ru)
*
|
2006-01-21 |
2011-11-20 |
Эбботт Гмбх Унд Ко.Кг |
Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ
|
|
US20070185145A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Royds Robert B |
Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
|
|
US7939567B2
(en)
*
|
2006-02-24 |
2011-05-10 |
Blue Blood Biotech Corp. |
Dextromethorphan-based method for treating acne
|
|
ZA200807571B
(en)
|
2006-03-01 |
2009-08-26 |
Ethypharm Sa |
Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
|
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
|
ATE536867T1
(de)
*
|
2006-03-16 |
2011-12-15 |
Tris Pharma Inc |
Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
|
|
GB0606124D0
(en)
*
|
2006-03-28 |
2006-05-03 |
Reckitt Benckiser Healthcare |
Buprenorphine derivatives and uses thereof
|
|
CN104825397A
(zh)
*
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
|
JP2009535409A
(ja)
*
|
2006-05-03 |
2009-10-01 |
コーワ ファーマシューティカルズ アメリカ，インコーポレイティド |
即効性ジクロフェナク−オピオイド組成物に基づく急性疼痛医薬
|
|
US10960077B2
(en)
*
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
|
SI2484346T1
(sl)
|
2006-06-19 |
2017-05-31 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
|
US8765178B2
(en)
|
2006-07-19 |
2014-07-01 |
Watson Laboratories, Inc. |
Controlled release formulations and associated methods
|
|
AU2011205222B2
(en)
*
|
2006-07-21 |
2014-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
|
ES2577390T3
(es)
|
2006-07-21 |
2016-07-14 |
Biodelivery Sciences International, Inc. |
Dispositivos de administración transmucosa con mayor captación
|
|
CA2671197A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophobic abuse deterrent delivery system
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
|
WO2008027442A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Theraquest Biosciences, Llc |
Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
|
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
|
US8187636B2
(en)
*
|
2006-09-25 |
2012-05-29 |
Atlantic Pharmaceuticals, Inc. |
Dosage forms for tamper prone therapeutic agents
|
|
CA2665726C
(en)
*
|
2006-10-11 |
2016-04-19 |
Alpharma, Inc. |
Pharmaceutical compositions
|
|
WO2008060964A2
(en)
|
2006-11-09 |
2008-05-22 |
Orexigen Therapeutics, Inc. |
Unit dosage package and methods for administering weight loss medications
|
|
DE102006054731B4
(de)
*
|
2006-11-21 |
2013-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
|
|
US8470361B2
(en)
|
2006-12-04 |
2013-06-25 |
Orexo Ab |
Non-abusable pharmaceutical composition comprising opioids
|
|
ES2763829T3
(es)
|
2007-02-01 |
2020-06-01 |
Sol Gel Tech Ltd |
Método para preparar partículas que comprenden un revestimiento de óxido de metal
|
|
EA200970724A1
(ru)
|
2007-02-01 |
2010-02-26 |
Сол-Джел Текнолоджиз Лтд. |
Композиции для местного применения, содержащие пероксид и ретиноид
|
|
GB2447014A
(en)
*
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
|
|
CA2678367C
(en)
*
|
2007-03-02 |
2014-07-08 |
Farnam Companies, Inc. |
Sustained release compositions using wax-like materials
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
|
CN105534936B
(zh)
|
2007-08-13 |
2020-07-31 |
Ohemo 生命科学股份有限公司 |
抗滥用药物、使用方法和制备方法
|
|
HUE027537T2
(en)
*
|
2007-09-03 |
2016-10-28 |
Nanotherapeutics Inc |
Granular preparations for the administration of poorly soluble drugs
|
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
EP2219612A4
(en)
*
|
2007-12-17 |
2013-10-30 |
Paladin Labs Inc |
FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
|
|
US20090196890A1
(en)
*
|
2007-12-17 |
2009-08-06 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical compositions
|
|
AU2015200313B2
(en)
*
|
2007-12-17 |
2016-12-01 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
EP2224915A4
(en)
*
|
2007-12-17 |
2014-01-22 |
Alpharma Pharmaceuticals Llc |
PHARMACEUTICAL COMPOSITIONS
|
|
CA2709903A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Oral opioid compositions with opioid antagonist
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
TWI454288B
(zh)
|
2008-01-25 |
2014-10-01 |
Gruenenthal Chemie |
藥物劑型
|
|
US9700552B2
(en)
|
2008-02-28 |
2017-07-11 |
Syntropharma Limited |
Pharmaceutical compositions for treatment of addiction
|
|
ES2599031T3
(es)
|
2008-05-09 |
2017-01-31 |
Grünenthal GmbH |
Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
|
|
CA2725930A1
(en)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
|
SI2317991T1
(sl)
*
|
2008-07-07 |
2017-09-29 |
Euro-Celtique S.A. |
Uporaba opioidnih antagonistov za zdravljenje retencije urina
|
|
WO2010044842A1
(en)
*
|
2008-10-16 |
2010-04-22 |
University Of Tennessee Research Foundation |
Tamper resistant oral dosage forms containing an embolizing agent
|
|
SI2352494T1
(sl)
*
|
2008-10-30 |
2019-12-31 |
Gruenenthal Gmbh |
Nove in potentne dozirne oblike tapentadola
|
|
EP2379111B1
(en)
*
|
2008-12-12 |
2013-03-20 |
Paladin Labs Inc. |
Narcotic drug formulations with decreased abuse potential
|
|
US8486449B2
(en)
|
2008-12-16 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
|
EP2381937A2
(en)
|
2008-12-31 |
2011-11-02 |
Upsher-Smith Laboratories, Inc. |
Opioid-containing oral pharmaceutical compositions and methods
|
|
WO2010099508A1
(en)
*
|
2009-02-26 |
2010-09-02 |
Theraquest Biosciences, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
|
PL2405915T3
(pl)
|
2009-03-10 |
2019-05-31 |
Euro Celtique Sa |
Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
|
|
CA2759870A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Phoeme Gmbh |
Particulate pharmaceutical composition with an opioid and an opioid antagonist
|
|
GB0909680D0
(en)
|
2009-06-05 |
2009-07-22 |
Euro Celtique Sa |
Dosage form
|
|
ES2534908T3
(es)
|
2009-07-22 |
2015-04-30 |
Grünenthal GmbH |
Forma de dosificación de liberación controlada extruida por fusión en caliente
|
|
BR112012001466A2
(pt)
*
|
2009-07-22 |
2020-08-11 |
Grünenthal GmbH |
forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
|
|
AU2009352681B2
(en)
|
2009-09-17 |
2014-11-20 |
Upsher-Smith Laboratories, Llc |
A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
|
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
ES2762113T3
(es)
|
2010-01-11 |
2020-05-22 |
Nalpropion Pharmaceuticals Inc |
Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
|
|
US9579285B2
(en)
|
2010-02-03 |
2017-02-28 |
Gruenenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
|
US9277748B2
(en)
|
2010-03-12 |
2016-03-08 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Agonist/antagonist compositions and methods of use
|
|
SG184523A1
(en)
*
|
2010-05-10 |
2012-11-29 |
Euro Celtique Sa |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
|
WO2011141490A1
(en)
*
|
2010-05-10 |
2011-11-17 |
Euro-Celtique S.A. |
Combination of active loaded granules with additional actives
|
|
MX340188B
(es)
*
|
2010-05-10 |
2016-06-30 |
Euro-Celtique S A * |
Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
|
|
EP2568977A1
(en)
|
2010-05-11 |
2013-03-20 |
Cima Labs Inc. |
Alcohol-resistant metoprolol-containing extended- release oral dosage forms
|
|
WO2012028318A1
(en)
|
2010-09-02 |
2012-03-08 |
Grünenthal GmbH |
Tamper resistant dosage form comprising an anionic polymer
|
|
CA2808219C
(en)
|
2010-09-02 |
2019-05-14 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising inorganic salt
|
|
DE102010048883A1
(de)
|
2010-10-19 |
2012-04-19 |
Lars Holger Hermann |
Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen
|
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
|
JP2012087101A
(ja)
*
|
2010-10-21 |
2012-05-10 |
Holger Hermann Lars |
オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
|
|
PL2826467T3
(pl)
|
2010-12-22 |
2018-01-31 |
Purdue Pharma Lp |
Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
|
|
PH12013501345A1
(en)
|
2010-12-23 |
2022-10-24 |
Purdue Pharma Lp |
Tamper resistant solid oral dosage forms
|
|
SG191208A1
(en)
*
|
2010-12-28 |
2013-07-31 |
Euro Celtique Sa |
A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
|
|
CN102068697B
(zh)
*
|
2010-12-30 |
2013-10-16 |
宜昌人福药业有限责任公司 |
含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
|
|
RU2013136350A
(ru)
|
2011-02-02 |
2015-03-27 |
АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи |
Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист
|
|
JP2014505736A
(ja)
|
2011-02-17 |
2014-03-06 |
キューアールエックスファーマ リミテッド |
固体投薬形態の乱用を防止するための技術
|
|
EP2726065A4
(en)
*
|
2011-06-30 |
2014-11-26 |
Neos Therapeutics Lp |
MISS-BROKEN MEDICINAL PRODUCTS
|
|
JP6063462B2
(ja)
|
2011-07-29 |
2017-01-18 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時薬剤放出を提供するタンパーレジスタント錠剤
|
|
BR112014002022A2
(pt)
|
2011-07-29 |
2017-02-21 |
Gruenenthal Gmbh |
comprimido resistente à violação proporcionando liberação de fármaco imediata
|
|
MX352959B
(es)
|
2011-08-18 |
2017-12-15 |
Biodelivery Sciences Int Inc |
Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
|
|
ME02153B
(me)
|
2011-09-19 |
2015-10-20 |
Orexo Ab |
Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
|
|
ES2603278T3
(es)
*
|
2011-12-09 |
2017-02-24 |
Purdue Pharma Lp |
Formas farmacéuticas de dosificación que comprenden poli (epsilon-caprolactona) y óxido de polietileno
|
|
EA201491164A1
(ru)
|
2011-12-12 |
2014-10-30 |
ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ |
Трансдермальная система доставки
|
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
|
SG10202012743WA
(en)
|
2011-12-21 |
2021-01-28 |
Biodelivery Sciences Int Inc |
Transmucosal drug delivery devices for use in chronic pain relief
|
|
BR112014019988A8
(pt)
|
2012-02-28 |
2017-07-11 |
Gruenenthal Gmbh |
Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
|
|
US9687445B2
(en)
|
2012-04-12 |
2017-06-27 |
Lts Lohmann Therapie-Systeme Ag |
Oral film containing opiate enteric-release beads
|
|
ES2716570T3
(es)
|
2012-04-17 |
2019-06-13 |
Purdue Pharma Lp |
Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
|
|
LT2838512T
(lt)
|
2012-04-18 |
2018-11-12 |
GrĆ¼nenthal GmbH |
Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
US10350227B2
(en)
|
2012-05-14 |
2019-07-16 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9694023B2
(en)
|
2012-05-14 |
2017-07-04 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9867839B2
(en)
|
2012-05-14 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US10080765B2
(en)
|
2012-05-14 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10028908B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9707245B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9949993B2
(en)
|
2012-05-14 |
2018-04-24 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9943531B2
(en)
|
2014-08-08 |
2018-04-17 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9782421B1
(en)
|
2012-05-14 |
2017-10-10 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US10111837B2
(en)
|
2012-05-14 |
2018-10-30 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds
|
|
US9211257B2
(en)
|
2012-05-14 |
2015-12-15 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9427403B2
(en)
|
2012-05-14 |
2016-08-30 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9867840B2
(en)
|
2014-05-27 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10028969B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9717747B2
(en)
|
2012-05-14 |
2017-08-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US10092581B2
(en)
|
2014-05-15 |
2018-10-09 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US11654152B2
(en)
|
2012-05-14 |
2023-05-23 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9999629B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9655908B2
(en)
|
2012-05-14 |
2017-05-23 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US9956237B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US10016446B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
|
|
US9844559B2
(en)
|
2012-05-14 |
2017-12-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesions
|
|
US10413561B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US9925203B2
(en)
|
2012-05-14 |
2018-03-27 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9861648B2
(en)
|
2012-05-14 |
2018-01-09 |
Antecip Boiventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US10493085B2
(en)
|
2012-05-14 |
2019-12-03 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US10173986B2
(en)
|
2012-05-14 |
2019-01-08 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9895383B2
(en)
|
2012-05-14 |
2018-02-20 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956234B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US9675626B2
(en)
|
2012-05-14 |
2017-06-13 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10016445B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9789128B2
(en)
|
2012-05-14 |
2017-10-17 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9999628B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9707247B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9662343B2
(en)
|
2012-05-14 |
2017-05-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9827192B2
(en)
|
2012-05-14 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10034890B2
(en)
|
2012-05-14 |
2018-07-31 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9669040B2
(en)
|
2012-05-14 |
2017-06-06 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10463682B2
(en)
|
2012-05-14 |
2019-11-05 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
|
|
US10413560B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9827256B2
(en)
|
2014-05-27 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating lower back pain
|
|
US9901589B2
(en)
|
2012-05-14 |
2018-02-27 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956238B2
(en)
|
2014-05-15 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9795622B2
(en)
|
2012-05-14 |
2017-10-24 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating pain associated with a joint
|
|
US8802658B2
(en)
|
2012-05-14 |
2014-08-12 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9616078B2
(en)
|
2012-05-14 |
2017-04-11 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9289441B2
(en)
|
2014-08-08 |
2016-03-22 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9877977B2
(en)
|
2012-05-14 |
2018-01-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10039773B2
(en)
|
2012-05-14 |
2018-08-07 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating arthritis
|
|
US10004756B2
(en)
|
2014-05-15 |
2018-06-26 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9820999B2
(en)
|
2012-05-14 |
2017-11-21 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9700570B2
(en)
|
2014-05-27 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9770457B2
(en)
|
2012-05-14 |
2017-09-26 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesion
|
|
US8865757B1
(en)
|
2014-05-28 |
2014-10-21 |
Antecip Bioventures Ii Llp |
Therapeutic compositions comprising imidazole and imidazolium compounds
|
|
PL4104824T3
(pl)
|
2012-06-06 |
2025-11-12 |
Nalpropion Pharmaceuticals Llc |
Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
|
|
US9730885B2
(en)
|
2012-07-12 |
2017-08-15 |
Mallinckrodt Llc |
Extended release, abuse deterrent pharmaceutical compositions
|
|
US9687465B2
(en)
|
2012-11-27 |
2017-06-27 |
Sol-Gel Technologies Ltd. |
Compositions for the treatment of rosacea
|
|
KR101659983B1
(ko)
|
2012-12-31 |
2016-09-26 |
주식회사 삼양바이오팜 |
용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
|
|
PE20151301A1
(es)
|
2013-02-05 |
2015-09-16 |
Purdue Pharma Lp |
Formulaciones farmaceuticas resistentes a la manipulacion indebida
|
|
US9517208B2
(en)
|
2013-03-15 |
2016-12-13 |
Purdue Pharma L.P. |
Abuse-deterrent dosage forms
|
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
|
US20140275038A1
(en)
|
2013-03-15 |
2014-09-18 |
Inspirion Delivery Technologies, Llc |
Abuse deterrent compositions and methods of use
|
|
ITTO20130284A1
(it)
*
|
2013-04-09 |
2014-10-10 |
Fond Istituto Italiano Di Tecnologia |
Procedimento per la produzione di microparticelle polimeriche sagomate
|
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
|
AU2014273227B2
(en)
*
|
2013-05-29 |
2019-08-15 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
|
WO2014195352A1
(en)
|
2013-06-04 |
2014-12-11 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal delivery system
|
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
|
KR20160034352A
(ko)
|
2013-07-23 |
2016-03-29 |
유로-셀티큐 에스.에이. |
장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
|
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
|
US20160256392A1
(en)
|
2013-10-31 |
2016-09-08 |
Cima Labs Inc. |
Abuse-deterrent dosage forms
|
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
JP6232135B2
(ja)
|
2013-11-13 |
2017-11-15 |
ユーロ−セルティーク エス．エイ． |
疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
|
|
HK1224189A1
(zh)
|
2013-11-26 |
2017-08-18 |
Grünenthal GmbH |
通过低温研磨制备粉状药物组合物
|
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|
|
US9480644B2
(en)
|
2014-03-14 |
2016-11-01 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US10085937B2
(en)
|
2014-03-14 |
2018-10-02 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
AU2015228541B2
(en)
|
2014-03-14 |
2020-09-03 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US9561177B2
(en)
|
2014-03-14 |
2017-02-07 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
|
US9872835B2
(en)
|
2014-05-26 |
2018-01-23 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
|
US9127069B1
(en)
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
|
US10493027B2
(en)
|
2014-08-07 |
2019-12-03 |
Mucodel Pharma Llc |
Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
|
|
US9682039B2
(en)
*
|
2014-08-07 |
2017-06-20 |
Mucodel Pharma Llc |
Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EP3229785A2
(de)
*
|
2014-12-08 |
2017-10-18 |
Develco Pharma Schweiz AG |
Naloxon-monopräparat und mehrschichttablette
|
|
FR3032353B1
(fr)
*
|
2015-02-06 |
2017-03-10 |
Jacques Seguin |
Composition pharmaceutique et dispositif pour le traitement de la douleur
|
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
|
CA2996281C
(en)
*
|
2015-08-31 |
2022-03-08 |
Regents Of The University Of Minnesota |
Opioid receptor modulators and use thereof
|
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
|
US20170065521A1
(en)
*
|
2015-09-09 |
2017-03-09 |
Micell Technologies, Inc. |
Biopharma application of micell technology
|
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
US9943513B1
(en)
|
2015-10-07 |
2018-04-17 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
|
GB201520390D0
(en)
*
|
2015-11-19 |
2016-01-06 |
Euro Celtique Sa |
Composition
|
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
|
US10532385B2
(en)
|
2016-06-29 |
2020-01-14 |
Disposerx, Inc. |
Disposal of medicaments
|
|
WO2018012627A1
(ja)
*
|
2016-07-15 |
2018-01-18 |
シャープ株式会社 |
送風装置および空気調和機
|
|
WO2018208241A1
(en)
*
|
2017-05-10 |
2018-11-15 |
İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi |
Formulation and optimization of controlled release tablets of morphine sulphate
|
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
|
JP2020526500A
(ja)
|
2017-06-30 |
2020-08-31 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
治療方法及びその剤形
|
|
HUE073201T2
(hu)
|
2017-07-12 |
2026-01-28 |
Sol Gel Tech Ltd |
Kapszulázott tretinoint tartalmazó készítmények
|
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
|
US12458592B1
(en)
|
2017-09-24 |
2025-11-04 |
Tris Pharma, Inc. |
Extended release amphetamine tablets
|
|
IL311303B2
(en)
*
|
2017-10-09 |
2026-05-01 |
Rhodes Pharmaceuticals Lp |
Medicinal resin components and methods for their production and use
|
|
EP3473246A1
(en)
|
2017-10-19 |
2019-04-24 |
Capsugel Belgium NV |
Immediate release abuse deterrent formulations
|
|
CA3075292A1
(en)
*
|
2017-10-20 |
2019-04-25 |
Purdue Pharma L.P. |
Pharmaceutical dosage forms
|
|
US12161754B2
(en)
|
2017-12-20 |
2024-12-10 |
Purdue Pharma L.P. |
Abuse deterrent morphine sulfate dosage forms
|
|
US10624856B2
(en)
|
2018-01-31 |
2020-04-21 |
Dharma Laboratories LLC |
Non-extractable oral solid dosage forms
|
|
CN109232748B
(zh)
*
|
2018-09-26 |
2019-06-11 |
哈尔滨工业大学 |
多位点修饰的脑啡肽与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
|
|
WO2020159901A1
(en)
*
|
2019-01-31 |
2020-08-06 |
Relmada Therapeutics, Inc. |
Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist
|
|
US11324707B2
(en)
|
2019-05-07 |
2022-05-10 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
US12589083B2
(en)
|
2019-05-07 |
2026-03-31 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
WO2021005501A1
(en)
*
|
2019-07-10 |
2021-01-14 |
Intas Pharmaceuticals Ltd. |
Naltrexone formulation
|
|
IT201900013473A1
(it)
*
|
2019-07-31 |
2021-01-31 |
Vetagro Int S R L |
Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
|
|
KR102908404B1
(ko)
*
|
2019-10-02 |
2026-01-12 |
하나제약 주식회사 |
옥시코돈 및 날록손을 포함하는 서방성 제제
|
|
EP3936112A1
(en)
*
|
2020-07-07 |
2022-01-12 |
Occlugel |
Hydrophilic degradable microspheres for delivering buprenorphine
|
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|
|
WO2023146983A1
(en)
*
|
2022-01-26 |
2023-08-03 |
Aardvark Therapeutics, Inc. |
Liquid resin extended-release oral naltrexone formulation for treating autism-related disorders
|
|
US12303604B1
(en)
|
2024-10-16 |
2025-05-20 |
Currax Pharmaceuticals Llc |
Pharmaceutical formulations comprising naltrexone and/or bupropion
|